Morgan Stanley Exec on the IPO Market and Robinhood's Tokenized Stocks
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
23 minutes ago
- Business Insider
GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (GQG) Gets a Buy from Morgan Stanley
Morgan Stanley analyst Andrei Stadnik maintained a Buy rating on GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh today and set a price target of A$3.04. The company's shares opened today at A$2.05. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Stadnik is a 4-star analyst with an average return of 5.7% and a 52.89% success rate. Stadnik covers the Financial sector, focusing on stocks such as Suncorp Group, Insurance Australia Group Limited, and Macquarie Group Limited. In addition to Morgan Stanley, GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh also received a Buy from RBC Capital's Jack Lynch in a report issued on July 21. However, yesterday, Morgans downgraded GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (ASX: GQG) to a Hold. The company has a one-year high of A$3.02 and a one-year low of A$1.71. Currently, GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh has an average volume of 3.55M.
Yahoo
10 hours ago
- Yahoo
S&P 500 now more likely to reach 7,200 next year, according to Morgan Stanley's Wilson
The new highs keep coming. Futures early Monday showed the S&P 500 on course for its 15th record of 2025. Tariff deals at levels that eight months ago would have been considered economically damaging are now welcomed by investors. And many analysts are embracing the optimism. Mike Wilson, Morgan Stanley's chief stock-market strategist, says he now is leaning more toward his bull case for the S&P 500 SPX, in a new note that published Monday. We're in our 70s with a $260K mortgage at 3% interest and $1.6 million in savings. Should we pay off our house in full? 'Vegas is not fun anymore': $9 cups of coffee and pricier rooms are steering travelers away from the vacation mecca The most important woman in bonds says investors now have unrealistic expectations That's 7,200 for the Wall Street benchmark in 12 months' time, based on earnings per share of $319 and a forward share price–to–earnings multiple of 22.5. Wilson says this view is grounded on a more resilient earnings and cash flow backdrop than previously expected, an improvement driven in part by AI adoption, dollar weakness, cash tax savings from the Trump administration's One Big Beautiful Bill Act and pent-up demand for many sectors in the market. Also, many parts of the stock market will benefit from easier growth comparisons, having experienced what Wilson terms 'rolling earnings recessions for the better part of the last 3 years.' And with private-sector wage growth in decline for the last several years — and AI adoption accelerating the phenomenon — this positive operating leverage should see profit margins expand. All told, earnings revision breadth has improved considerably in recent months, he says. The high probability of Federal Reserve rate cuts in the first quarter of 2026 will also be a boon for stocks. Indeed, the likelihood of easier monetary policy is one reason Wilson is comfortable with applying the historically high 22.5 multiple. 'On that score, our regime analysis shows that when EPS growth is above the long-term median and the fed-funds rate is down on a year-over-year basis (our house views by mid-2026), the market multiple expands 90% of the time,' Wilson says. With regard to tariffs, he acknowledges they may be a problem for consumer-goods companies, in which he suggests investors should be underweight. But overall the 'rate of change on policy uncertainty peaked back in April as stocks troughed.' Wilson's favored sector is industrials, even though he notes it's already the best performing in the S&P 500 to date in 2025 and over the last month. 'Relative earnings revisions remain durable, capacity utilization is stabilizing, and aggregate C&I [commercial and industrial] loans have surpassed $2.8 trillion (the highest level since 2020),' he writes. Companies likely to benefit from domestic infrastructure spending, particularly related to technology, include Rockwell Automation ROK, Eaton ETN, Trane Technologies TT and Johnson Controls International JCI. Despite Wilson's positivity going into 2026, he accepts that the near-term set-up is not without risks, including stubbornly high longer-term Treasury yields, tariff-related inflation and seasonal stock-market headwinds. 'Thus, we do expect some consolidation tactically, but would reiterate that we expect pullbacks to be shallow, and we're buyers of dips,' he says. U.S. stock-indices SPX DJIA COMP are slightly higher at the opening bell as benchmark Treasury yields BX:TMUBMUSD10Y reverse early falls. The dollar index DXY is up, while oil prices CL.1 jump and gold GC00 is trading around $3,336 an ounce. Key asset performance Last 5d 1m YTD 1y S&P 500 6388.64 1.46% 3.49% 8.62% 17.03% Nasdaq Composite 21,108.32 1.02% 4.12% 9.31% 21.61% 10-year Treasury 4.374 -1.00 14.60 -20.20 19.50 Gold 3339.3 -2.08% 0.73% 26.52% 40.22% Oil 65.71 -0.11% 1.14% -8.57% -13.45% Data: MarketWatch. Treasury yields change expressed in basis points Need to Know starts early and is updated until the opening bell, but to get it delivered once to your email box. The emailed version will be sent out at about 7:30 a.m. Eastern. The U.S. and European Union agreed a trade deal over the weekend that increases tariffs on most E.U. exports to the U.S. to 15%. The U.S. and China will conduct more trade talks on Monday in Sweden. A busy week of possible market catalysts include U.S. second quarter GDP and the Federal Reserve policy decision on Wednesday, and the July nonfarm payrolls report on Friday. It's also a big few days for corporate earnings, with highlights being Meta META and Microsoft MSFT on Wednesday, followed on Thursday by Apple AAPL and Amazon AMZN. Elon Musk said Tesla TSLA has signed a $16.5 billion deal with Samsung Electronics KR:005930 to produce new-generation chips for the electric-vehicle maker. Crypto lenders dial up risk with 'microfinance on steroids' How to extract $400 million from a billionaire: Use a Gilded Age family name. Confessions of a laptop farmer: How an American helped North Korea's wild remote worker scheme. Clifford Asness, the hedge-fund manager and co-founder of AQR Capital Management, delivered on X this succinct observation regarding market conditions right now. Here were the most active stock-market ticker symbols on MarketWatch as of 6 a.m. Eastern. Ticker Security name TSLA Tesla NVDA Nvidia PLUS ePlus PLTR Palantir Technologies GME GameStop AMD Advanced Micro devices OPEN Opendoor Technologies NIO NIO AAPL Apple TSM Taiwan Semiconductor Manufacturing Zookeepers in Prague turn into puppeteers to save baby vultures. A good walk spoiled. Introducing 'Golf Force One'. Dressing gown bishop tells church choir to 'leave my house'. For more market updates plus actionable trade ideas for stocks, options and crypto, . Royal Caribbean stock gets rocked despite higher demand for cruises. Here's why. SoFi's stock soars as earnings bring surging loan growth and a number of records Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
14 hours ago
- Business Wire
Saltgrass Advisory Launches to Power the Next Wave of Healthcare AI Innovation
CHARLESTON, S.C.--(BUSINESS WIRE)--Saltgrass Advisory, a strategic management consulting firm focused on artificial intelligence and emerging healthcare technologies, today announced its official launch. The firm partners with healthcare institutions, startups, and investors to accelerate high-impact innovation by turning cutting-edge capabilities into scalable, real-world solutions. 'Saltgrass Advisory brought the strategic insight and healthcare expertise we needed to define and commercialize our oncology AI innovation,' said Brett Berman, director of operations - health solutions, Medical University of South Carolina. Saltgrass Advisory is led by seasoned executives who bring a rare blend of healthcare, data, and AI expertise. Robert Goodman leverages his track record as a data & AI leader at Deloitte and as an executive within Blackstone-and Vista-backed technology companies. Brian Litten draws on decades as a healthcare operator, including a successful NASDAQ IPO with Tabula Rasa in 2016, his roles as CEO of PathForward Oncology and Swift Medical, and deep leadership experience across the Blue Cross network. Together they're positioning Saltgrass as a trusted partner to drive healthcare innovation at scale. With AI evolving rapidly—and healthcare organizations under growing pressure to deliver better outcomes at lower cost—Saltgrass Advisory enters the market at a pivotal time. The firm guides leaders through this transformation with a focus on intelligent infrastructure, clinical relevance, and operational execution. Impact in Action Saltgrass Advisory is already delivering measurable impact, recently guiding the Medical University of South Carolina (MUSC) on the commercialization of its oncology AI platform, LAMPER, which has driven: an 80% reduction in support staff burden per patient, a 10–20% increase in clinical trial accrual, and 3–4 hours saved per patient across roles. Time-to-appointment readiness has dropped from 1–2 days to under a day. In just one department at MUSC, LAMPER is projected to deliver $2.1M–$10.2M in cost savings over five years, while unlocking new revenue through increased patient throughput and clinical trial enrollment. 'Saltgrass Advisory brought the strategic insight and healthcare expertise we needed to define and commercialize our oncology AI innovation,' said Brett Berman, director of operations, MUSC Health. 'Their team translated academic discovery into real-world impact.' Focused Expertise at the Intersection of Strategy, Technology, and Delivery Saltgrass Advisory—powered by a leadership team of seasoned operators who've built, scaled, and exited companies across the healthcare ecosystem—helps clients accelerate outcomes and unlock healthcare value: Commercialization and go-to-market execution AI strategy, data platforms, intelligent models, seamless integrations, and scalable operations Fractional leadership across product, operations, technology, and growth 1:1 advisory for institutional leaders and startup founders Regulatory, compliance, and policy navigation The Saltgrass Team Brian Litten, Managing Partner – Former digital health founder & CEO Robert Goodman, Managing Partner – Former data & AI executive at Deloitte Lisa Davis, Principal– Past CIO of top U.S. health plan; Former SVP, Intel Health Solutions Munish Khaneja, MD, Principal – Former health plan CMO, EmblemHealth and HealthEdge Drew Narayan, Principal – Former strategy leader at Blue Cross Blue Shield of North Carolina Archana Puthran, Principal – Former AI & digital health leader at UnitedHealth, OptumRx Jacob Jesson, Principal – Former EVP & chief revenue and experience officer, Medecision Paige Bagby – Principal - Former Ogilvy communications and public relations leader Speaker Series Saltgrass Advisory is live, and so is its new speaker series highlighting concrete steps to scale health AI. The series debuts August 19 at 11 a.m. ET. Register here. About Saltgrass Advisory
